Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Jesse M. Tettero; Lok Lam Ngai; Costa Bachas; Dimitri A. Breems; Thomas Fischer; Bjorn T. Gjertsen; Patrycja Gradowska; Laimonas Griskevicius; Jeroen J. W. M. Janssen; Gunnar Juliusson; Johan Maertens; Markus G. Manz; Thomas Pabst; Jakob Passweg; Kimmo Porkka; Peter J. M. Valk; Bob Löwenberg; Gert J. Ossenkoppele; Jacqueline Cloos

doi:https://doi.org/10.3324/haematol.2022.282639

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjorn T. Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J. W. M. Janssen, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter J. M. Valk, Bob Löwenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

Not available.

Original language	English
Pages (from-to)	2794-2798
Number of pages	5
Journal	Haematologica
Volume	108
Issue number	10
Early online date	6 Apr 2023
DOIs	https://doi.org/10.3324/haematol.2022.282639
Publication status	Published - 1 Oct 2023

Access to Document

https://doi.org/10.3324/haematol.2022.282639

Cite this

Tettero, J. M., Ngai, L. L., Bachas, C., Breems, D. A., Fischer, T., Gjertsen, B. T., Gradowska, P., Griskevicius, L., Janssen, J. J. W. M., Juliusson, G., Maertens, J., Manz, M. G., Pabst, T., Passweg, J., Porkka, K., Valk, P. J. M., Löwenberg, B., Ossenkoppele, G. J., & Cloos, J. (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica, 108(10), 2794-2798. https://doi.org/10.3324/haematol.2022.282639

@article{d06853ae16fb45ccb65fd03ac524f767,

title = "Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival",

abstract = "Not available.",

author = "Tettero, {Jesse M.} and Ngai, {Lok Lam} and Costa Bachas and Breems, {Dimitri A.} and Thomas Fischer and Gjertsen, {Bjorn T.} and Patrycja Gradowska and Laimonas Griskevicius and Janssen, {Jeroen J. W. M.} and Gunnar Juliusson and Johan Maertens and Manz, {Markus G.} and Thomas Pabst and Jakob Passweg and Kimmo Porkka and Valk, {Peter J. M.} and Bob L{\"o}wenberg and Ossenkoppele, {Gert J.} and Jacqueline Cloos",

note = "Funding Information: This study was supported by the Dutch Cancer Society (n. ALPE- 2013-6371). Funding Information: This study was supported by the Dutch Cancer Society (n. ALPE-",

year = "2023",

month = oct,

day = "1",

doi = "https://doi.org/10.3324/haematol.2022.282639",

language = "English",

volume = "108",

pages = "2794--2798",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "10",

}

Tettero, JM , Ngai, LL , Bachas, C, Breems, DA, Fischer, T, Gjertsen, BT, Gradowska, P, Griskevicius, L, Janssen, JJWM, Juliusson, G, Maertens, J, Manz, MG, Pabst, T, Passweg, J, Porkka, K, Valk, PJM, Löwenberg, B, Ossenkoppele, GJ & Cloos, J 2023, 'Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival', Haematologica, vol. 108, no. 10, pp. 2794-2798. https://doi.org/10.3324/haematol.2022.282639

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. / Tettero, Jesse M.; Ngai, Lok Lam ; Bachas, Costa et al.
In: Haematologica, Vol. 108, No. 10, 01.10.2023, p. 2794-2798.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

AU - Tettero, Jesse M.

AU - Ngai, Lok Lam

AU - Bachas, Costa

AU - Breems, Dimitri A.

AU - Fischer, Thomas

AU - Gjertsen, Bjorn T.

AU - Gradowska, Patrycja

AU - Griskevicius, Laimonas

AU - Janssen, Jeroen J. W. M.

AU - Juliusson, Gunnar

AU - Maertens, Johan

AU - Manz, Markus G.

AU - Pabst, Thomas

AU - Passweg, Jakob

AU - Porkka, Kimmo

AU - Valk, Peter J. M.

AU - Löwenberg, Bob

AU - Ossenkoppele, Gert J.

AU - Cloos, Jacqueline

N1 - Funding Information: This study was supported by the Dutch Cancer Society (n. ALPE- 2013-6371). Funding Information: This study was supported by the Dutch Cancer Society (n. ALPE-

PY - 2023/10/1

Y1 - 2023/10/1

N2 - Not available.

AB - Not available.

UR - http://www.scopus.com/inward/record.url?scp=85174080198&partnerID=8YFLogxK

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85174080198&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/37021540

U2 - https://doi.org/10.3324/haematol.2022.282639

DO - https://doi.org/10.3324/haematol.2022.282639

M3 - Article

C2 - 37021540

SN - 0390-6078

VL - 108

SP - 2794

EP - 2798

JO - Haematologica

JF - Haematologica

IS - 10

ER -

Tettero JM , Ngai LL , Bachas C, Breems DA, Fischer T, Gjertsen BT et al. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica. 2023 Oct 1;108(10):2794-2798. Epub 2023 Apr 6. doi: https://doi.org/10.3324/haematol.2022.282639

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Abstract

Access to Document

Other files and links

Cite this